Clinton campaign was ‘Shattered’ regardless of outcome
The title of the book detailing the history of the campaign for president by a former First Lady, senator and Secretary of State was going be “Shattered” whether Hillary Rodham Clinton won or lost, Amie Parnes told a National Press Club Book Rap.
Parnes and her co-author, Jonathan Allen, said their title worked either way — If Clinton won it would be that she shattered the glass ceiling and if (when) she lost it was a shattered campaign. The complete title of the book is “Shattered: Inside Hillary Clinton’s Doomed Campaign.”
The authors interviewed more than 100 people who worked on Clinton’s run during the campaign and after the election. They said they would not report anything until after the vote. After the election people they had not previously interviewed “came out of woodwork,” they said.
Though their book may seem hard on the campaign, the goal was to create a history of it, they said. They believe the book attempts to show Clinton’s humanity.
A major problem with the Clinton drive was there was “no big idea,” they said. She made no case for herself, instead she focused on trying to disqualify her opponents –- Sen. Bernie Sanders, an independent from Vermont, in the primaries, and businessman Donald Trump, the Republican nominee during the general election.
The lack of a big idea meant voters had no reason to support her. Sanders and Trump had enthusiastic supporters while Clinton did not. Clinton understood she was not reaching voters but she never figured out how to solve the problem, they said. Read more here, from the National Press Club.
One In 5 Cancers Diagnosed in The U.S. Is a Rare Cancer
About one in five cancer diagnoses in the United States is a rare cancer, according to a new American Cancer Society report. The report, appearing in CA: A Cancer Journal for Clinicians, a peer-reviewed journal of the American Cancer Society, finds rare cancers account for more than two in three cancers occurring in children and adolescents. The authors say the proportion of rare cancers is likely to grow as the use of molecular markers to classify cancers increases.
Rare cancers present unique challenges for clinicians and their patients. For most rare cancers, research to identify causes or to develop strategies for prevention or early detection is limited or nonexistent. In addition, rare cancers can be challenging to diagnose, often resulting in numerous physician visits, misdiagnoses, and substantial delays in diagnosis.
Treatment options for rare cancers are often more limited and less effective than for more common cancers, partly because there is less preclinical research and fewer clinical trials for rare cancers, which are often limited to select high-volume cancer centers. Consequently, rare cancers have become an area of priority for some researchers and public health advocates.